Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

India pins hopes on locally-tested COVID-19 vaccines given Pfizer constraints

11/17/2020 | 08:56am EST
Checks ahead of Hindu festival of Diwali amidst COVID-19 in Ahmedabad

NEW DELHI (Reuters) - India hopes five locally-tested vaccines will help it to control COVID-19, as those developed by Pfizer and Moderna may not be available to it in big quantities soon.

The five candidates include Russia's Sputnik-V whose "Phase-II going to Phase-III" trials in India will start next week in collaboration with Dr Reddy's Laboratories, Vinod Paul, the head of a committee advising the prime minister, said.

The other experimental vaccines are the one being developed by AstraZeneca and Oxford University which is being manufactured by the Serum Institute of India; Bharat Biotech and the Indian government's COVAXIN; Zydus Cadila's ZyCoV-D and lastly one being developed by Biological E. Ltd alongside Baylor College of Medicine and Dynavax Technologies Corp.

Paul told a news briefing that AstraZeneca vaccine's last-stage trials in India had gone well and had almost been completed. The country of 1.35 billion people has reported 8.87 million infections, second only to the United States, and 130,519 deaths as a result of COVID-19.

"We are very hopeful that we will be successful with the five vaccines," Paul said on Tuesday. "They are easy platforms, availability of doses is very high. They will be able to control our pandemic in terms of the numbers of doses required."

Paul said the government was also watching the progress of the Pfizer and Moderna vaccines, both of which have said interim results of last-stage trials of their candidates showed that they were more than 90% effective.

Unlike Pfizer's vaccine which must be kept at minus 70 degrees Celsius or below, Moderna's can be stored at normal fridge temperatures, making it more suited for poorer countries such as India where cold chains are limited.

"This obviously will be a very big hindrance to scale up the vaccine," Paul said of Pfizer's, adding that if India finds itself needing to do so it will pursue this option.

"If we are required to form our strategy on this particular vaccine, then we will proceed with it. Though, even if we get it, we will get it in a few months only. But talks are ongoing."

(Reporting by Krishna N. Das; Editing by Alexander Smith)

By Krishna N. Das

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.44% 7592 Delayed Quote.3.21%
DR. REDDY'S LABORATORIES LIMITED -1.93% 5207.6 End-of-day quote.0.07%
DYNAVAX TECHNOLOGIES CORPORATION -0.19% 5.13 Delayed Quote.15.51%
MODERNA, INC. -0.05% 129.65 Delayed Quote.24.17%
PFIZER INC. -0.14% 36.7 Delayed Quote.-0.16%
All news about ASTRAZENECA PLC
01:59pMODERNA : WHO sees poorer countries getting first COVID vaccines this quarter
11:49aASTRAZENECA : Brazil airlifts emergency oxygen in, sick babies out of pandemic-b..
11:29aASTRAZENECA : Deutsche Bank Initiates Coverage on AstraZeneca With Buy Rating
11:10aEuropean ADRs Move Sharply Lower in Friday Trading
07:36aSouth Africa's mining industry to support COVID-19 vaccine rollout
07:28aASTRAZENECA : Nepal clears AstraZeneca vaccine for emergency use
06:00aASTRAZENECA : Buy rating from Deutsche Bank
04:38aASTRAZENECA : Obtains European Approval for Imfinzi's Expanded Dosing Option
03:48aASTRAZENECA : Buy rating from Berenberg
03:19aAstraZeneca lung cancer drug gets nod for new dosing regimen in EU, UK
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,1x
Yield 2020 2,72%
Capitalization 136 B 135 B -
EV / Sales 2020 5,67x
EV / Sales 2021 4,92x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,42 $
Spread / Highest target 50,9%
Spread / Average Target 22,0%
Spread / Lowest Target -18,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271